PO.ET02.04 · 实验与分子治疗
Antibody-Drug Conjugates and Linker Engineering 4
- 5631 5631 TCX-201, a novel ADC targeting a specific tumor-associated carbohydrate antigen (TACA) with excellent preclinical efficacy, PK and safety profile in solid tumor models Matthias Ocker, Francesco Muraca, Stephan Grunwald, Wiebke Winkler, Karla E. G. Soto, Carolin Lange, Jean Engela, Peter Sondermann
-
- 5633 5633 YB-811, a novel antibody drug conjugate targeting the tumor-selective human neuronal pentraxin receptor shows pronounced efficacy in experimental tumor models Peter Schiemann, Michel Janicot, Gunther Wennemuth, Mykola Lyndin
- 5634 5634 KY102, a novel Glypican 3-targeting nanobody drug conjugate bearing a topoisomerase 1 inhibitor payload demonstrates compelling preclinical activity in hepatocellular carcinoma models Haikun Shi
-
-
- 5637 5637 A novel EGFR and B7H3 dual-targeted antibody-drug conjugate (ADC) for the treatment of solid tumors Mingkun Zhang, Xuguo Zhu, Jun Wang, Jing Zhao
-
- 5639 5639 HDP-103, a PSMA targeting amanitin-based ADC, is efficacious even in difficult to treat patient derived xenograft models with heterogenous PSMA expression Kristin Decker, Christian Orlik, Irina Dranova, Anikó Palfi, Torsten Hechler, Andreas Pahl, Michael Kulke
-
- 5641 5641 BCG037, a first-in-class anti-human ALPP/ALPG therapeutic ADC that inhibits tumor growth in pancreatic cancer and gastric cancer PDX models Yong Xie, Peiran Li, Ying Zhu, Yanan Guo
-
- 5643 5643 Preclinical characterization of RC118 ADC and identification of its differential binding pattern relative to other anti-CLDN18.2 antibodies Lili Wang, Xiaoping Zhang, Mingyang Li, Xiao Wang, Yidan Xu, Xiaoli He, Shengle Ji, Shuya Ji, Shifu Wang, Yinghao Xin, Fanxue Bu, Yuelei Shen, Jianmin Fang, Yuanhao Li
- 5644 5644 DA-3501 (AT-211): Evaluation of immune-mediated antitumor activity and combination immunotherapy potential of a site-specific CLDN18.2-targeting antibody-drug conjugate (ADC) Kyoung-Ho Pyo, Seong-Hyun Park, Dongsop Lee, Haneol Kim, Younggyu Kong, Younggeun Lee, Hojin Yeom, Sowon Aum, Sun Hee Park, Huijo Oh, Cheyeon Kim, Hyeonseok Jin, Hyeonseok Jin, Aera Lee, Hojeong Hong, Ju Hwan Kim, Hyungseok Choi, Mi-Kyung Kim, Taedong Han
-
- 5647 5647 GS24-B057, a potential best-in-class Nectin-4- and Trop-2-directed bispecific ADC, for the treatment of urothelial carcinoma and other solid tumors Meihan Li, Fu Li, Qiuru Che, Xiaojing Huang, Dongxia Chu, Qiyang Zhang, Nan Li, Qingjuan Ma, Weiming He, Wenqiang Zhai, Yihui Lin, Xiaozhen Wang, Fanglong Yang, Siqing Wang, Lei Jin, John L. Xu
-
-
-
- 5651 5651 Preclinical development of LUA005: A differentiated bivalent EGFR/cMET bispecific ADC displays strong anti-cancer efficacy and a wider therapeutic window Lei Han, Ken Qin, Ying huang, Xi Xiao, Zhebin Zhang, Wei Wang, Wei Zheng, Hai Wu, Xiaoshuang Yan, Dongdong Wu, Shuyong Zhao, Ling Zhang, Yang Yang, Hua Ying, Weikang Tao
- 5652 5652 Preclinical development of LUA011, a novel CDH17/cMET bispecific ADC with enhanced antitumor efficacy and mitigated gastrointestinal toxicity Guoyin Huang, Ken Qin, Man Wu, Lei Han, Ying Huang, Wei Zheng, Xiaoshuang Yan, luchan deng, Hai Wu, Wenshu Huang, Shuyong Zhao, Ling Zhang, Yang Yang, Hua Ying, Weikang Tao
-
-
-
- 5656 5656 Characterization and translational development of novel pre|CISION® technology compounds delivering complementary dual payloads to the tumor microenvironment following FAP cleavage Victoria Juskaite, Tom Clough, Ellen Watts, Iva Zlatareva, Folake Orafidiya, Hanna Buist, Alexa Kennedy, Jannah Jeon, Greg Billenness, Douglas Sammon, Sophie Brown, Curtis Rink, Ruairidh Edwards, Vidicha Chunilal, Manuel Pinto, Dave Liebowitz, Francis Wilson, Michelle Morrow, David Jones
- 5657 5657 A novel bispecific ADC to treat solid tumors by removing immunosuppression in the tumor microenvironment Shiva Bhowmik, William Brady
-
